Reviewer's report

**Title:** A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy

**Version:** 2  **Date:** 21 May 2013

**Reviewer:** Yoshihiro Tatsumi

**Reviewer's report:**

The authors study that effectiveness and toxicity of SRBT for local prostate cancer.

The authors show excellent date of biochemical progression-free survival rate.

My major comments are as follows.

1) The authors didn't show that definition of biochemical recurrence. I guess that they use the Phoenix definition, because they describe the Phoenix definition in Result. Thus, I easily understand, they described definition of biochemical recurrence in Methods.

2) The criteria that they performed mono therapy SRBT or SRBT with ADT is not unclear. They described only that patients received ADT determined by the urologist opinion. I want to know that what kind of patient received ADT. Because, I think that combined ADT greatly influence the result of biochemical recurrence.

3) Are there any other toxicities except urinary and rectal toxicities? The authors show only urinary and rectal toxicities. I want to know there are no any other toxicities, such as myelosuppression etc.

Here are the minor comments.

4) An abbreviated word don’t spell out for use first time. I noticed that ‘FFBF’and ‘PTV’ didn’t spell out

**Level of interest:** An article of outstanding merit and interest in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests.